FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement...
Aignostics announced the launch of HETA Clinical, a new family of pan-cancer AI products spanning the pathology workflow from intake and evaluation to mole...
Systech, a global leader in pharmaceutical serialization and traceability solutions, has launched the ST33 Carton Serialization Station and ST34 Carton Ser...
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing...
Salvia BioElectronics, a clinical-stage medical device company pioneering a novel neuromodulation therapy for people with resistant migraine, announced tha...
Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, announced...
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed i...
New designation expands on first Fast Track Designation in TMB-H colorectal cancer and is supported by monotherapy responses across m...
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjug...
As demand for injectable therapies grows and manufacturing requirements become more complex, Vetter Pharma is expanding its global fill-finish network to...
Northwestern Medicine, Chicago’s premier integrated academic health system, and OpenEvidence, a leading AI-powered medical search and clinical decisi...
GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced that it signed a Memorandum of Unders...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new dr...
In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF o...
© 2026 Biopharma Boardroom. All Rights Reserved.
